stoxline Quote Chart Rank Option Currency Glossary
  
Invitae Corporation (NVTA)
0.5739  -0.02 (-3.32%)    12-07 16:00
Open: 0.6046
High: 0.6098
Volume: 5,155,461
  
Pre. Close: 0.5936
Low: 0.5514
Market Cap: 164(M)
Technical analysis
2023-12-07 4:22:26 PM
Short term     
Mid term     
Targets 6-month :  0.85 1-year :  0.99
Resists First :  0.73 Second :  0.85
Pivot price 0.55
Supports First :  0.5 Second :  0.36
MAs MA(5) :  0.58 MA(20) :  0.54
MA(100) :  0.8 MA(250) :  1.29
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  63.1 D(3) :  65.7
RSI RSI(14): 50.2
52-week High :  2.94 Low :  0.36
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NVTA ] has closed below upper band by 31.5%. Bollinger Bands are 58.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.61 - 0.61 0.61 - 0.62
Low: 0.54 - 0.55 0.55 - 0.55
Close: 0.57 - 0.57 0.57 - 0.58
Company Description

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Headline News

Tue, 05 Dec 2023
Better Growth Stock: CRISPR Therapeutics vs. Invitae - The Globe and Mail

Thu, 09 Nov 2023
Invitae Corporation (NYSE:NVTA) Q3 2023 Earnings Call Transcript - Yahoo Finance

Wed, 08 Nov 2023
Invitae Reports Third Quarter 2023 Financial Results - PR Newswire

Sat, 04 Nov 2023
3 Things About Invitae Every Smart Investor Knows - The Motley Fool

Wed, 01 Nov 2023
Is Invitae Stock a Buy Now? - The Motley Fool

Wed, 01 Nov 2023
Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Diagnostics & Research
Shares Out 286 (M)
Shares Float 284 (M)
Held by Insiders 0.9 (%)
Held by Institutions 66.2 (%)
Shares Short 50,970 (K)
Shares Short P.Month 52,300 (K)
Stock Financials
EPS -5.37
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.78
Profit Margin -299.2 %
Operating Margin -84.9 %
Return on Assets (ttm) -23.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -9.2 %
Gross Profit (p.s.) 0.34
Sales Per Share 1.68
EBITDA (p.s.) -1.24
Qtrly Earnings Growth 0 %
Operating Cash Flow -238 (M)
Levered Free Cash Flow -35 (M)
Stock Valuations
PE Ratio -0.11
PEG Ratio -0.1
Price to Book value -0.16
Price to Sales 0.34
Price to Cash Flow -0.7
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android